Assenat, Eric
Pageaux, Georges-Philippe
Thézenas, Simon
Peron, Jean-Marie
Bécouarn, Yves
Seitz, Jean-François
Merle, Philippe
Blanc, Jean-Frédéric
Bouché, Olivier
Ramdani, Mohamed
Poujol, Sylvain
de Forges, Hélène
Ychou, Marc
Boige, Valérie
Funding for this research was provided by:
Bayer HealthCare (NA)
Article History
Received: 6 September 2018
Revised: 8 March 2019
Accepted: 14 March 2019
First Online: 4 April 2019
Competing interests
: E.A. reports personal fees from Bayer, Sirtex, Novartis, Ipsen and Sanofi, and travel and expenses from Bayer and Ipsen, outside the submitted work. P.M. reports personal fees from Bayer outside the submitted work. J.F.B. reports personal fees from Bayer, outside the submitted work. O.B. reports personal fees (board and speaker) from Amgen, Roche, Merck Sereno, Bayer, and from Pierre Fabre, Novartis and Lilly, outside the submitted work. All other authors have nothing to disclose regarding the present study.
: All patients signed an informed consent before entering the study. The study protocol was approved by an ethical review board (Comité de Protection des Personnes Sud Méditerrannée IV, September 2<sup>nd</sup>, 2008; EudraCT number: 2008-000123-26) and was conducted in accordance with the good clinical practice and Declaration of Helsinki guidelines.
: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).